Latest Angiogenesis inhibitors Stories
A protein that has been at the center of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA).
This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer.
Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival.
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting.
- A trick or prank.